AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8341859
Drug: Salbutamol (S;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (S; 0.2 mg)
Trial: 3786603
Drug: Intravenous GABA
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GABA administration
Trial: 19713950
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR therapy (placebo-controlled trial)
Trial: 18652113
Drug: Allopurinol tablet
RxNorm normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol tablet
Trial: 15975300
Drug: Xuesaitong soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuesaitong soft capsule (XST)
Trial: 15975300
Drug: Dahuang Zhechong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dahuang Zhechong pill (NFDA1)
Trial: 14769157
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program for health personnel including social, cultural, and economic aspects of tuberculosis, diagnosis and treatment, and establishment of self-help groups. Patients received a short-term treatment regimen with isoniazid, rifampin, pyrazinamide, and ethambutol for 25 weeks (105 doses).
Trial: 14769157
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard treatment without the educational intervention.
Trial: 1406078
Drug: Recombinant alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha‐2b interferon treatment 3 MU three times weekly for 36 weeks
Trial: 27846344
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg monthly for 76 weeks)
Trial: 22840762
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation (TMS) treatment to the left temporoparietal cortex for 10 days
Trial: 20820916
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg twice daily
Trial: 18549466
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (TG)
Trial: 18549466
Drug: Dihydrotestosterone gel
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone gel (DHTG)
Trial: 17299466
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose vitamin A (5000 IU per day)
Trial: 17299466
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose vitamin A (200,000 IU)
Trial: 11292011
Drug: Ayahuasca (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (0.5 mg DMT/kg body weight)
Trial: 11292011
Drug: Ayahuasca (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (0.75 mg DMT/kg body weight)
Trial: 11292011
Drug: Ayahuasca (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (all doses)
Trial: 11292011
Drug: Ayahuasca (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (medium dose)
Trial: 9331003
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8, 12, or 16 mg)
Trial: 3221745
Drug: (R)-propafenone 250
RxNorm normalized name: (+)-(r)-propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-propafenone 250 mg
Trial: 3221745
Drug: (S)-propafenone 250
RxNorm normalized name: (-)-(S)-Propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-propafenone 250 mg
Trial: 30001760
Drug: Step 15
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 15 exposure therapy (allowing a spider to walk freely over one's body)
Trial: 30001760
Drug: Step 14
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Step 14 or fewer exposure therapy steps
Trial: 25720854
Drug: ASR implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASR implants
Trial: 25720854
Drug: ReCap implants
RxNorm normalized name: recAP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReCap implants
Trial: 22147343
Drug: Chinese preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese preparation of rhGH (GenHeal®, 1.6 mg (4 IU), Shanghai, China) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Trial: 22147343
Drug: Swiss preparation
RxNorm normalized name: Swiss Kriss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swiss preparation of rhGH (Saizen®, 1.33 mg (4 IU), Laboratoires Serone S.A., Switzerland) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Trial: 18972290
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (BDP; 400 microg/d)
Trial: 15614573
Drug: 0.42 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.42 mg/kg dexamphetamine
Trial: 22030902
Drug: Dual cholate
RxNorm normalized name: cholate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual cholate (CA) clearance after oral administration (Cl(oral))
Trial: 22030902
Drug: CA Cl(oral)
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA Cl(oral) or PHM
Trial: 15983093
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose (5 g in 50 ml)
Trial: 15983093
Drug: 50% dextrose
RxNorm normalized name: DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dextrose (5 g in 10 ml)
Trial: 16843455
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg twice daily)
Trial: 8520499
Drug: Myeloablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative therapy supported by autologous bone marrow or blood stem cell transplantation
Trial: 1836486
Drug: Accelerated vaccination
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated vaccination schedule with recombinant hepatitis B vaccine (Engerix-B)
Trial: 6769666
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (500 mg) in fasting (A)
Trial: 6769666
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (500 mg) with a meal (B)
Trial: 6769666
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (500 mg) 3 hours after a meal (C)
Trial: 6769666
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus dose of VPA (400 mg) 3 hours after a meal
Trial: 27574418
Drug: Self-management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management program (group education session, individual training on inhalation techniques, written action plan)
Trial: 17295569
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment negative ratings
Trial: 17295569
Drug: Positive ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive ratings in the 1st half of treatment
Trial: 16232343
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of Bacillus Calmette‐Guérin polysaccharide nucleotide (BCG‐PSN)
Trial: 16232343
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of BCG‐PSN
Trial: 16232343
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of BCG‐PSN (36 times)
Trial: 11793634
Drug: Celecoxib as
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib as adjunctive therapy
Trial: 10783843
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Ultra Plaque Remover (D9)
Trial: 11350520
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B 3D Plaque Remover (3D)
Trial: 2727071
Drug: Developmental physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmental physical therapy program (six one-minute activities in side-lying and supported-sitting positions)
Trial: 2727071
Drug: Developmental physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmental physical therapy program
Trial: 799561
Drug: Metoprolol (75-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (75-300 mg)
Trial: 31483155
Drug: Acute antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute antioxidant (AO) administration (600 mg α-lipoic acid, 1,000 mg vitamin C, and 600 IU vitamin E)
Trial: 31483155
Drug: Acute antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute antioxidant (AO) administration
Trial: 16461147
Drug: Peanut flour
RxNorm normalized name: Peanut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut flour (doses ranging from 10 microg to 3 g)
Trial: 16461147
Drug: Peanut flour
RxNorm normalized name: Peanut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut flour (doses ranging from 10 mg to 3 g)
Trial: 15238773
Drug: Oral ALCAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ALCAR (1500 mg twice daily) for up to 33 months
Trial: 9300221
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human insulin-like growth factor-1 (rhIGF-I)
Trial: 3534801
Drug: 112.5 mg
RxNorm normalized name: lotilaner 112.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 112.5 mg hydrochlorothiazide
Trial: 22709745
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy on the background of early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Trial: 21164555
Drug: Flavored water
RxNorm normalized name: FLAVOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored water with 6% carbohydrate and 18 mmol·L‐1 NaCl (CNa)
Trial: 12799509
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (PnCRM9)
Trial: 12799509
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (meningococcus C vaccine)
Trial: 10423078
Drug: Newer classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer classes of blood pressure lowering drugs
Trial: 2580164
Drug: Captopril and
RxNorm normalized name: captopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril and Enalapril (combined therapy)
Trial: 2580164
Drug: Captopril and
RxNorm normalized name: captopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril and Enalapril (after prolonged treatment)
Trial: 30017552
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75–100 mg)
Trial: 30017552
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of aspirin (≥325 mg)
Trial: 24201303
Drug: Conventional programming
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional programming with therapy for ventricular tachycardia ≥170 bpm
Trial: 24201303
Drug: High-rate cutoff
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-rate cutoff with therapy for ventricular tachycardia ≥200 bpm and a monitoring zone at 170 to 199 bpm
Trial: 24201303
Drug: Prolonged 60-second
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged 60-second delay with a monitoring zone before therapy
Trial: 23128163
Drug: AMG145 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 280 mg
Trial: 23128163
Drug: AMG145 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 350 mg
Trial: 23128163
Drug: AMG145 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 420 mg
Trial: 23128163
Drug: AMG145 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 420 mg + Ezetimibe 10 mg
Trial: 23128163
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Ezetimibe 10 mg
Trial: 21410069
Drug: Menatetrenone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (4 5mg daily, orally)
Trial: 17961145
Drug: Oral 17‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17‐beta estradiol
Trial: 17961145
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and vaginal 17‐beta estradiol
Trial: 16632842
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anesthesia (CSA) with titration of 2.5 mg boluses every 15 min of isobaric bupivacaine
Trial: 16632842
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection spinal anesthesia (SA) with 7.5 mg of isobaric bupivacaine
Trial: 11267624
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral hydrocortisone
Trial: 11267624
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral hydrocortisone
Trial: 9884705
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (surgery + radiotherapy)
Trial: 7857512
Drug: Hypericum extracts
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extracts (dosage: 300 to 900 mg total extract daily; duration: 2 to 6 weeks)
Trial: 2543207
Drug: CAVE chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAVE chemotherapy + RA233
Trial: 2543207
Drug: CAVE chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAVE chemotherapy
Trial: 29426608
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) at a dose of 10 mg/kg intravenously, 10 min preoperatively and 5 h postoperatively
Trial: 26224543
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg once daily, n=125)
Trial: 12732880
Drug: G‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF alone (10 mcg/kg/day)
Trial: 12732880
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus G‐CSF (Cyclophosphamide at 4 g/m(2) and G‐CSF at 10 mcg/kg/day)
Trial: 10199772
Drug: GHRP-2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRP-2 plus TRH infusion (1 + 1 microg/kg x h) for 5 days
Trial: 348293
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide, adriamycin, and 5‐fluorouracil (CAF)
Trial: 348293
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Trial: 31286426
Drug: Hand hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand hygiene education programme with digital tools (interactive android-based tablets)
Trial: 25982568
Drug: Combined setting
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined setting of one night wake therapy followed by 2 weeks bright light therapy
Trial: 25982568
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy alone
Trial: 16919506
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy with sustained-release tolterodine alone
Trial: 16919506
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy with sustained-release tolterodine combined with behavioral training (pelvic floor muscle exercise training, bladder control techniques, fluid management)
Trial: 16919506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug withdrawal and behavioral training stopped)
Trial: 16563280
Drug: Weight-adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dose rt-PA (42-92 mg, 1 mg/kg body weight)
Trial: 16563280
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rt-PA (42 mg over 90 minutes)
Trial: 16563280
Drug: Weight-adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dose rt-PA
Trial: 16563280
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rt-PA
Trial: 12189776
Drug: Chewing gums
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gums (Superpep forte, 20 mg dimenhydrinate each, chewed for 30 min)
Trial: 12189776
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dimenhydrinate tablet
Trial: 7851574
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) depot, 1.88 mg
Trial: 7851574
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) depot, 3.75 mg
Trial: 6935550
Drug: gemfibrozil (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil (1600 mg daily)
Trial: 25407420
Drug: Food preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food preparation activities
Trial: 22431131
Drug: Colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.75 g/day orally
Trial: 17211699
Drug: Synbiotic 2000
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic 2000 (once daily dose)
Trial: 8729614
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (radiotherapy followed by chemotherapy)
Trial: 9802715
Drug: Metronidazole 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 25% dental gel applied subgingivally on days 0 and 7
Trial: 27752485
Drug: Mindfulness-integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-integrated cognitive behavior therapy
Trial: 22727611
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg coadministered with fimasartan 240 mg
Trial: 11788225
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (diuretics or beta-blockers)
Trial: 7726351
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of 20 ml of 1% lidocaine
Trial: 7726351
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of morphine sulfate and midazolam
Trial: 7211734
Drug: Full cream
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full cream milk
Trial: 7211734
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (skim milk, yoghurt, full cream milk)
Trial: 25191915
Drug: Low-dose buprenorphine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose buprenorphine
Trial: 17267744
Drug: FIR therapy
RxNorm normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIR therapy for 1 year